ATRA : Insider Transactions for Atara Biotherapeutics, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Atara Biotherapeutics, Inc. (ATRA)

$0.53

0.04 (7.08%) as of 4:30 Fri 6/7

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

108,674,000

Market Cap:

57.47(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.2298 - $2.31

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 707

Guru Rank Value : 1.9

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	816,825	816,825
Total Buy Value	$0	$0	$194,885	$194,885
Total People Bought	0	0	3	3
Total Buy Transactions	0	0	4	4
Total Shares Sold	211,204	267,396	419,842	591,605
Total Sell Value	$130,313	$170,773	$340,560	$980,941
Total People Sold	5	5	6	9
Total Sell Transactions	5	10	23	41
End Date	2024-03-10	2023-12-08	2023-06-09	2022-06-09

Adjust Filter Settings

Records found: 736

Page 12 of 30

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Chief Tech. Operations Officer

• – –

2018-10-01

4

AS

$41.02

$61,918

D/D

(1,500)

31,858

-

Chief Tech. Operations Officer

• – –

2018-10-01

4

OE

$20.40

$30,600

D/D

1,500

33,358

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2018-09-26

4

AS

$43.08

$581,580

D/D

(13,500)

286,355

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2018-09-25

4

AS

$40.26

$546,905

D/D

(13,500)

299,855

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2018-09-24

4

AS

$39.74

$718,425

D/D

(18,000)

313,355

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-09-22

4

D

$39.85

$3,161,221

D/D

(79,328)

733,285

-

EVP & Chief Strategy Officer

• – –

2018-09-22

4

D

$39.85

$882,996

D/D

(22,158)

243,966

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-09-19

4

AS

$39.99

$155,961

I/I

(3,900)

58,678

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-09-18

4

AS

$39.62

$154,518

I/I

(3,900)

62,578

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-09-07

4

AS

$39.74

$155,881

I/I

(3,900)

66,478

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-09-06

4

AS

$38.45

$151,041

I/I

(3,900)

70,378

-

Chief Tech. Operations Officer

• – –

2018-09-04

4

AS

$39.16

$59,178

D/D

(1,500)

31,858

-

Chief Tech. Operations Officer

• – –

2018-09-04

4

OE

$20.40

$30,600

D/D

1,500

33,358

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-08-21

4

AS

$36.69

$143,091

I/I

(3,900)

74,278

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-08-20

4

AS

$36.04

$140,556

I/I

(3,900)

78,178

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2018-08-15

4

AS

$37.54

$29,094

D/D

(775)

331,355

-

EVP & Chief Strategy Officer

• – –

2018-08-15

4

D

$35.90

$13,714

D/D

(382)

266,124

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-08-07

4

AS

$37.35

$145,785

I/I

(3,900)

82,078

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-08-06

4

AS

$37.48

$146,172

I/I

(3,900)

85,978

-

Chief Tech. Operations Officer

• – –

2018-08-01

4

AS

$37.09

$56,610

D/D

(1,500)

31,858

-

Chief Tech. Operations Officer

• – –

2018-08-01

4

OE

$20.40

$30,600

D/D

1,500

33,358

-

Chief Tech. Operations Officer

• – –

2018-07-30

4

AS

$35.64

$357,787

D/D

(10,000)

31,858

-

Chief Tech. Operations Officer

• – –

2018-07-30

4

OE

$20.40

$204,000

D/D

10,000

41,858

-

Chief Financial Officer

• – –

2018-07-27

4

B

$36.80

$73,600

D/D

2,000

47,000

2.74

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2018-07-27

4

AS

$36.55

$144,211

I/I

(3,900)

89,878

-

736 Records found	Previous 10 11 12 13 14 15 16 17 18 19 Next	Page 12 of 30

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.